Navigation Links
Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
Date:7/22/2008

Two Regimens Including Lantus(R) and Apidra(R) Resulted in Significant Reductions in A1C in Patients with Type 2 Diabetes, Whatever the Algorithm

Used

BRIDGEWATER, N.J., July 22 /PRNewswire/ -- Results from the "Adjust to Target in Type 2 Diabetes: Comparison of a Simple Algorithm to Carbohydrate Counting for Adjustment of Mealtime Insulin Glulisine" study, were published in the American Diabetes Association's (ADA) medical journal, Diabetes Care. This study, using a basal-bolus insulin regimen with Lantus(R) (insulin glargine [rDNA origin] injection) once daily (basal insulin) and rapid-acting Apidra(R) (insulin glulisine [rDNA origin] injection) at mealtime (bolus insulin) demonstrated significant reductions in postprandial blood glucose and A1C using two different dosing algorithms.

The 24-week, multicenter, randomized, controlled study compared two algorithms for adjusting mealtime insulin (Apidra(R)) in 273 intent-to-treat patients with type 2 diabetes. Apidra(R) and Lantus(R) were adjusted weekly in both groups based on the previous week's self-monitored blood glucose (SMBG) results. One group, the "Simplified Algorithm" group, was provided set doses of Apidra(R) to take before each meal. The second group, the "Carbohydrate Counting" group, was provided an insulin-to-carbohydrate ratio to use for each meal and adjusted their Apidra(R) dose based on amount of carbohydrate consumed. After 24 weeks, the percentage of patients who achieved A1C<7 percent -- the ADA's recommended target for blood sugar control -- while following these two treatment algorithms were 73% and 69% (P=0.70), respectively.

Average A1C levels at week 24 were 6.70 in the Simplified Algorithm group and 6.54 percent in the Carb Counting group. The respective mean A1C changes from baseline to 24 weeks were -1.46 percent and -1.59 percent (P=.24). A1C <7.0 percent was achieved by 73 percent (Simplified Algorithm) and 69 percent (C
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
4. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Newly Approved HIV Drug Shows Great Promise
7. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
8. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
9. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 This report analyzes the worldwide markets ... following Product Segments: SPECT Systems (Includes SPECT and SPECT/CT systems), ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin ... forecasts are provided for the period 2013 through 2020. Also, ...
(Date:9/16/2014)... 3SBio Inc., ("3SBio") a leading biotechnology ... focusing on researching, developing, manufacturing and marketing biopharmaceutical ... an exclusive license agreement with JenKem Technology Co., ... in Mainland China of PEG-irinotecan, a long-acting polymer-drug ... over-expressed in many solid tumors, including colorectal, ovarian, ...
(Date:9/16/2014)... The Pulmonary Fibrosis Foundation (PFF) announced today that it ... and families suffering from pulmonary fibrosis (PF) to the ... Drug Development Meeting for Idiopathic Pulmonary Fibrosis on September ... patient input in order to better understand patients, needs ... the FDA for focusing its attention on this devastating ...
Breaking Medicine Technology:Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 263SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4
... CHICAGO, June 9, 2011 Today a Cook County jury ... Chicago area man, Steven Johansen, who was administered Baxter blood ...  This was the first of hundreds of pending lawsuits on ... are pending in the Circuit Court of Cook County in ...
... Inc. today announced an agreement with the U.S. Department of ... the marketing and promotion of Keppra®, an anti-epileptic prescription medicine. ... this investigation occurred more than six years ago, and as ... United States since learning of the investigation in 2008. ...
Cached Medicine Technology:Nolan Law Group: Jury Finds Against Baxter Healthcare In Nation's First Contaminated Chinese Heparin Case 2UCB, Inc. Resolves Investigation of Past Keppra® Marketing and Promotional Activities 2
(Date:9/17/2014)... 17, 2014 “North America Gynecological ... data on the North America Gynecological Devices market. ... dollars, volume (in units) and average prices (in ... Female Sterilization Devices (Transcervical Sterilization Devices ... Rings)) , Endometrial Ablation Devices (Thermal ...
(Date:9/17/2014)... September 17, 2014 Stand Up for ... music, returns to the Theater at Madison Square Garden, ... Bob Woodruff Foundation (BWF) and New York Comedy Festival ... service members, veterans and their families. , The ... Mulaney, John Oliver, Bruce Springsteen, Brian Williams and other ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 ... Screeners (NAPBS®) Background Screening Credentialing Council (BSCC) ... compliance with the Background Screening Agency Accreditation ... recognized as BSCC-Accredited. , S2Verify, LLC, ... Each year, U.S. employers, organizations and governmental ...
(Date:9/17/2014)... 2014 Market Research Report on ... in-depth research report on the China DEHP Plasticizer ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:9/17/2014)... Steven Reinberg HealthDay Reporter ... the same day that President Barack Obama announced a significant ... crisis, the World Health Organization warned Tuesday that the window ... start doubling every three weeks. Obama said he will ... and logistical support to beleaguered health care facilities in Guinea, ...
Breaking Medicine News(10 mins):Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 3Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 4Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 2Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 3Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 4Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 5Health News:S2Verify Achieves Background Screening Credentialing Council Accreditation 2Health News:S2Verify Achieves Background Screening Credentialing Council Accreditation 3Health News:DEHP Plasticizer Industry & SiC Substrates Market Analysis For (NA, Asia, Europe & ROW) Research Now at DeepResearchReports.com 2Health News:DEHP Plasticizer Industry & SiC Substrates Market Analysis For (NA, Asia, Europe & ROW) Research Now at DeepResearchReports.com 3Health News:Obama Steps Up Aid to Fight Ebola in West Africa 2Health News:Obama Steps Up Aid to Fight Ebola in West Africa 3
... This release is available in German . ... problem in AIDS . Shortly after an individual becomes infected ... in this organ for life. Many HIV-infected individuals experience disturbances ... dementia. How the virus causes brain disease is still unclear. ...
... Fla., March 4 Viles & Beckman,LLC revealed today ... killed or crippled by side effects, such as renal ... into patients while,undergoing open heart surgery -- Trasylol -- ... Trasylol was recalled from the US market in,November 2007 ...
... LA JOLLA, CA A nuclear receptor protein, known ... also exerts powerful anti-inflammatory effects in arteries, suppressing atherosclerosis ... to new research by scientists at the Salk Institute ... Health. , Their findings, reported in this weeks ...
... for shamans and herb women? Not at all, for many ... products or were developed on the basis of natural substances. ... made from yew trees. The popular periwinkle plant, which grows ... of vinca alkaloids that are effective, for example, against malignant ...
... Developer,s Foundation to Lead the ... Ending Global Hunger, Improving Nutrition, NEW YORK, March ... a $15 million challenge grant to transform The Hebrew,University ... in Rehovot, Israel. The gift will be the cornerstone ...
... in training have a 17 percent less chance of ... surgery at non-teaching hospitals, according to results of a ... the Annals of Thoracic Surgery. , Theres a ... because of training issues, and concerns are frequently voiced ...
Cached Medicine News:Health News:Neural progenitor cells as reservoirs for HIV in the brain 2Health News:Drug Risk Harms 10,000+ Floridians 2Health News:New potential drug target for the treatment of atherosclerosis 2Health News:New potential drug target for the treatment of atherosclerosis 3Health News:Screening the herbal pharmacy 2Health News:Robert H. Smith 'Feeding the Future' with $15 Million Gift to Hebrew University of Jerusalem 2Health News:Risk of surgery for lung cancer lower at teaching hospitals 2
... QFill2 is the ideal system for fast, accurate ... pressure driven, pinch valve controlled dispensing mechanism, ensures ... all of the components that come into contact ... clean, and autoclave. The unique compact design saves ...
... system for fast, accurate filling of 96 or ... controlled dispensing mechanism, ensures that no liquid can ... that come into contact with the liquid path ... unique compact design saves valuable bench space and ...
... Personal Pipettor is a cost-effective ... pipetting needs, from reagent additions ... more. Systems are available in ... using either fixed or disposable ...
... the newest addition to Thermos Multidrop family. ... of 1-50 l into 384- and 96-well ... a 384-well plate takes only 14 s. ... accuracy typically 10% at 2 l, which ...
Medicine Products: